List view / Grid view
PrecisionLife’s Dr Sayoni Das, a computational biologist who leads the research and development of bioinformatics pipelines that generate biological insights from PrecisionLife’s core technology and support drug discovery programmes, details a new study. Using combinatorial analysis, genetic variants associated with long COVID have been identified and, furthermore, it has been…
Receiving a COVID-19 vaccination could offer a dual benefit by not only lowering the likelihood of developing long-haul COVID but also mitigating symptoms for individuals already dealing with this condition.
In this Q&A, Dr Steve Gardner elucidates the genetic variations that appear to underpin the debilitating new condition, long COVID, that have been uncovered in a recent analytical study.
10 to 20 percent of individuals that get COVID-19 will be later diagnosed with long COVID. New research looks at blood plasma protein patterns that can improve patient outcomes.
Swiss researchers have found a new class of 'good autoantibodies', which are associated with a favourable course and lower risk of long-Covid.
Drug discovery trends in 2023 will change the way we conduct science and result in entirely new, more efficient, and effective research paradigms. Through increased public-private partnerships, multidisciplinary collaboration and patient engagement in the drug discovery process, we will see new vaccines and therapies getting to the public faster and…
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
Researchers have developed a 3D “assembloid” that presents a potential entry route of COVID-19 into the brain.
Scientists have shown that the SARS-CoV-2 Spike protein can initiate gene expression changes, potentially explaining long COVID symptoms.
The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
